141.65 USD
-3.65 (-2.51%)
137.2 USD
-4.45 (-3.14%)
Taking everything into account, ILMN scores 5 out of 10 in our fundamental rating. ILMN was compared to 57 industry peers in the Life Sciences Tools & Services industry. ILMN has an excellent profitability rating, but there are some minor concerns on its financial health. ILMN has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
- In the past year ILMN was profitable.
- In the past year ILMN had a positive cash flow from operations.
- In multiple years ILMN reported negative net income over the last 5 years.
- ILMN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of 11.38%, ILMN belongs to the top of the industry, outperforming 91.23% of the companies in the same industry.
- ILMN has a better Return On Equity (29.53%) than 96.49% of its industry peers.
- ILMN's Return On Invested Capital of 16.40% is amongst the best of the industry. ILMN outperforms 91.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.38% | ||
| ROE | 29.53% | ||
| ROIC | 16.4% |
ROA(3y)-22.28%
ROA(5y)-10.63%
ROE(3y)-46.16%
ROE(5y)-23.48%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin of ILMN (16.39%) is better than 89.47% of its industry peers.
- ILMN has a Operating Margin of 20.41%. This is amongst the best in the industry. ILMN outperforms 85.96% of its industry peers.
- In the last couple of years the Operating Margin of ILMN has declined.
- Looking at the Gross Margin, with a value of 66.74%, ILMN belongs to the top of the industry, outperforming 87.72% of the companies in the same industry.
- In the last couple of years the Gross Margin of ILMN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.41% | ||
| PM (TTM) | 16.39% | ||
| GM | 66.74% |
OM growth 3YN/A
OM growth 5Y-11.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.07%
GM growth 5Y-1.23%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), ILMN is creating some value.
- Compared to 1 year ago, ILMN has about the same amount of shares outstanding.
- Compared to 5 years ago, ILMN has more shares outstanding
- The debt/assets ratio for ILMN is higher compared to a year ago.
2.2 Solvency
- ILMN has an Altman-Z score of 4.58. This indicates that ILMN is financially healthy and has little risk of bankruptcy at the moment.
- The Altman-Z score of ILMN (4.58) is better than 75.44% of its industry peers.
- ILMN has a debt to FCF ratio of 1.99. This is a very positive value and a sign of high solvency as it would only need 1.99 years to pay back of all of its debts.
- ILMN has a Debt to FCF ratio of 1.99. This is amongst the best in the industry. ILMN outperforms 87.72% of its industry peers.
- A Debt/Equity ratio of 0.42 indicates that ILMN is not too dependend on debt financing.
- ILMN's Debt to Equity ratio of 0.42 is in line compared to the rest of the industry. ILMN outperforms 40.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.42 | ||
| Debt/FCF | 1.99 | ||
| Altman-Z | 4.58 |
ROIC/WACC1.5
WACC10.92%
2.3 Liquidity
- A Current Ratio of 1.43 indicates that ILMN should not have too much problems paying its short term obligations.
- ILMN's Current ratio of 1.43 is on the low side compared to the rest of the industry. ILMN is outperformed by 77.19% of its industry peers.
- ILMN has a Quick Ratio of 1.12. This is a normal value and indicates that ILMN is financially healthy and should not expect problems in meeting its short term obligations.
- ILMN has a Quick ratio of 1.12. This is in the lower half of the industry: ILMN underperforms 68.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.43 | ||
| Quick Ratio | 1.12 |
3. Growth
3.1 Past
- ILMN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 152.02%, which is quite impressive.
- Measured over the past years, ILMN shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -17.93% on average per year.
- Looking at the last year, ILMN shows a decrease in Revenue. The Revenue has decreased by -2.32% in the last year.
- The Revenue has been growing slightly by 4.29% on average over the past years.
EPS 1Y (TTM)152.02%
EPS 3Y-25.65%
EPS 5Y-17.93%
EPS Q2Q%17.54%
Revenue 1Y (TTM)-2.32%
Revenue growth 3Y-1.15%
Revenue growth 5Y4.29%
Sales Q2Q%0.37%
3.2 Future
- Based on estimates for the next years, ILMN will show a very strong growth in Earnings Per Share. The EPS will grow by 24.95% on average per year.
- Based on estimates for the next years, ILMN will show a small growth in Revenue. The Revenue will grow by 3.99% on average per year.
EPS Next Y96.03%
EPS Next 2Y44.64%
EPS Next 3Y34.05%
EPS Next 5Y24.95%
Revenue Next Year-0.88%
Revenue Next 2Y0.73%
Revenue Next 3Y2.34%
Revenue Next 5Y3.99%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 32.49, which means the current valuation is very expensive for ILMN.
- Compared to the rest of the industry, the Price/Earnings ratio of ILMN indicates a somewhat cheap valuation: ILMN is cheaper than 66.67% of the companies listed in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 27.38, ILMN is valued at the same level.
- Based on the Price/Forward Earnings ratio of 27.64, the valuation of ILMN can be described as expensive.
- Based on the Price/Forward Earnings ratio, ILMN is valued a bit cheaper than the industry average as 73.68% of the companies are valued more expensively.
- ILMN's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 24.29.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 32.49 | ||
| Fwd PE | 27.64 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, ILMN is valued a bit cheaper than 78.95% of the companies in the same industry.
- 87.72% of the companies in the same industry are more expensive than ILMN, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 21.64 | ||
| EV/EBITDA | 19.24 |
4.3 Compensation for Growth
- ILMN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- ILMN has a very decent profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as ILMN's earnings are expected to grow with 34.05% in the coming years.
PEG (NY)0.34
PEG (5Y)N/A
EPS Next 2Y44.64%
EPS Next 3Y34.05%
5. Dividend
5.1 Amount
- No dividends for ILMN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
141.65
-3.65 (-2.51%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)10-30 2025-10-30/amc
Earnings (Next)02-05 2026-02-05/amc
Inst Owners104.7%
Inst Owner Change0.5%
Ins Owners0.17%
Ins Owner Change-0.21%
Market Cap21.64B
Revenue(TTM)4.29B
Net Income(TTM)703.00M
Analysts73.33
Price Target132.25 (-6.64%)
Short Float %4.46%
Short Ratio4.02
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.9%
Min EPS beat(2)12.52%
Max EPS beat(2)15.27%
EPS beat(4)3
Avg EPS beat(4)5.34%
Min EPS beat(4)-7.76%
Max EPS beat(4)15.27%
EPS beat(8)6
Avg EPS beat(8)97.15%
EPS beat(12)10
Avg EPS beat(12)231.96%
EPS beat(16)13
Avg EPS beat(16)178.01%
Revenue beat(2)0
Avg Revenue beat(2)-0.74%
Min Revenue beat(2)-1.21%
Max Revenue beat(2)-0.28%
Revenue beat(4)0
Avg Revenue beat(4)-0.66%
Min Revenue beat(4)-1.21%
Max Revenue beat(4)-0.18%
Revenue beat(8)3
Avg Revenue beat(8)-0.29%
Revenue beat(12)4
Avg Revenue beat(12)-0.57%
Revenue beat(16)5
Avg Revenue beat(16)-0.78%
PT rev (1m)7.1%
PT rev (3m)16.16%
EPS NQ rev (1m)-0.24%
EPS NQ rev (3m)3.5%
EPS NY rev (1m)-0.01%
EPS NY rev (3m)4.26%
Revenue NQ rev (1m)-0.18%
Revenue NQ rev (3m)0.54%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)0.53%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 32.49 | ||
| Fwd PE | 27.64 | ||
| P/S | 5.05 | ||
| P/FCF | 21.64 | ||
| P/OCF | 19.29 | ||
| P/B | 9.09 | ||
| P/tB | 20.75 | ||
| EV/EBITDA | 19.24 |
EPS(TTM)4.36
EY3.08%
EPS(NY)5.13
Fwd EY3.62%
FCF(TTM)6.54
FCFY4.62%
OCF(TTM)7.34
OCFY5.18%
SpS28.06
BVpS15.58
TBVpS6.83
PEG (NY)0.34
PEG (5Y)N/A
Graham Number39.1
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.38% | ||
| ROE | 29.53% | ||
| ROCE | 20.76% | ||
| ROIC | 16.4% | ||
| ROICexc | 23.54% | ||
| ROICexgc | 43.23% | ||
| OM | 20.41% | ||
| PM (TTM) | 16.39% | ||
| GM | 66.74% | ||
| FCFM | 23.32% |
ROA(3y)-22.28%
ROA(5y)-10.63%
ROE(3y)-46.16%
ROE(5y)-23.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-6.48%
ROICexc growth 3YN/A
ROICexc growth 5Y-9.28%
OM growth 3YN/A
OM growth 5Y-11.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.07%
GM growth 5Y-1.23%
F-Score7
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.42 | ||
| Debt/FCF | 1.99 | ||
| Debt/EBITDA | 0.86 | ||
| Cap/Depr | 44.36% | ||
| Cap/Sales | 2.85% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 97.57% | ||
| Profit Quality | 142.25% | ||
| Current Ratio | 1.43 | ||
| Quick Ratio | 1.12 | ||
| Altman-Z | 4.58 |
F-Score7
WACC10.92%
ROIC/WACC1.5
Cap/Depr(3y)66.6%
Cap/Depr(5y)76.75%
Cap/Sales(3y)5.82%
Cap/Sales(5y)5.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)152.02%
EPS 3Y-25.65%
EPS 5Y-17.93%
EPS Q2Q%17.54%
EPS Next Y96.03%
EPS Next 2Y44.64%
EPS Next 3Y34.05%
EPS Next 5Y24.95%
Revenue 1Y (TTM)-2.32%
Revenue growth 3Y-1.15%
Revenue growth 5Y4.29%
Sales Q2Q%0.37%
Revenue Next Year-0.88%
Revenue Next 2Y0.73%
Revenue Next 3Y2.34%
Revenue Next 5Y3.99%
EBIT growth 1Y154.36%
EBIT growth 3YN/A
EBIT growth 5Y-7.67%
EBIT Next Year36.79%
EBIT Next 3Y17.14%
EBIT Next 5Y16.22%
FCF growth 1Y495.24%
FCF growth 3Y28.14%
FCF growth 5Y-3.38%
OCF growth 1Y179.8%
OCF growth 3Y15.37%
OCF growth 5Y-4.45%
ILLUMINA INC / ILMN FAQ
Can you provide the ChartMill fundamental rating for ILLUMINA INC?
ChartMill assigns a fundamental rating of 5 / 10 to ILMN.
Can you provide the valuation status for ILLUMINA INC?
ChartMill assigns a valuation rating of 6 / 10 to ILLUMINA INC (ILMN). This can be considered as Fairly Valued.
How profitable is ILLUMINA INC (ILMN) stock?
ILLUMINA INC (ILMN) has a profitability rating of 7 / 10.
What is the financial health of ILLUMINA INC (ILMN) stock?
The financial health rating of ILLUMINA INC (ILMN) is 5 / 10.
What is the expected EPS growth for ILLUMINA INC (ILMN) stock?
The Earnings per Share (EPS) of ILLUMINA INC (ILMN) is expected to grow by 96.03% in the next year.